Shares of Morepen Laboratories Ltd. surged over 7% to ₹58.35 on the NSE in Thursday’s trade following the announcement of four major product launches across critical therapeutic segments. The stock opened at ₹54.52 and touched an intraday high of ₹58.00, adding strong momentum to its recent rally.
Company eyes ₹1,000 crore formulation business
Morepen Labs launched Ticapen, UdoFix, LycoMore, and Acifix, aimed at addressing high-burden diseases in cardiology, hepatology, gastroenterology, and nutritional therapy. The company, which already commands a strong position in APIs, now targets ₹1,000 crore in branded formulations over the next five years, up from its current ₹325 crore business.
The products were developed using in-house APIs at its USFDA-approved facilities in Himachal Pradesh and are backed by strategic pricing and advanced packaging features.
Market reaction and outlook
With a market cap of ₹31,680 crore, a P/E ratio of 24.08, and 5.59 million average volume, the stock remained one of the top gainers on NSE today. The strong investor response highlights confidence in Morepen’s formulation growth roadmap and new product pipeline.
As per management, the company is also scaling its footprint in international markets, leveraging strong R&D and regulatory approvals across 82 countries. This expansion includes high-growth regions like the US and Europe.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
